Formula I Antiprotozoal Compound for High Clearance and Safety
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for protozoan infections, such as giardiasis, amoebiasis, and cryptosporidiosis, face challenges including low efficacy, adverse side effects, resistance development, and limited safety for pregnant and lactating individuals, necessitating a more effective and safer antiprotozoal agent with a novel mechanism of action.
Innovation Solution
Administration of a therapeutically effective amount of a compound of Formula I or its stereoisomer, tautomer, pharmaceutically acceptable salt, or prodrug, which includes specific structural features, to treat or prevent protozoan colonization or infection, offering high clearance rates, mild adverse effects, and resistance to existing treatment-resistant protozoa.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing antiprotozoal agents (metronidazole, tinidazole, nitazoxanide) are used, then treatment coverage is provided, but efficacy is suboptimal with curative rates ranging from 60-89%
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of existing antiprotozoal agents through systematic variation of R groups in Formula I. This structural parameter modification aims to achieve superior efficacy (≥90% curative rate) and complete clearance of protozoan infections, directly addressing the suboptimal performance of current drugs.
2Reliability
If treatment duration is extended to 5-10 days with metronidazole, then higher curative rates are achieved, but compliance deteriorates due to missed treatments and poor patient adherence
Solution Approach 1:
The patent employs periodic action principles by designing a compound administration regimen that achieves high curative rates through optimized dosing intervals and duration. The compound of Formula I is intended to maintain effective concentrations over the treatment period while improving compliance compared to conventional 5-10 day metronidazole courses.
3Reliability
If existing antiprotozoal agents are used, then treatment is provided, but resistance development occurs widely experienced with available treatments
Solution Approach 1:
The patent applies the inversion principle by developing a novel compound with a different mechanism of action compared to existing antiprotozoal agents. By inverting the approach from modifying existing drugs to creating a structurally distinct agent (Formula I), the patent aims to overcome resistance that has developed against conventional treatments.
4Reliability
If metronidazole is administered, then antiprotozoal effect is achieved, but adverse effects occur including metallic taste, nausea, headache, vertigo, leukopaenia, insomnia, and irritability
Solution Approach 1:
The patent applies the extraction principle by separating the therapeutic antiprotozoal effect from the adverse effects associated with metronidazole. Through structural modification (Formula I with varied R groups), the patent aims to extract and retain the beneficial protozoan-killing activity while eliminating or reducing the harmful side effects such as metallic taste, nausea, and neurological symptoms.
5Reliability
If quinacrine is used for treatment, then antiprotozoal activity is achieved, but serious side effects occur including psychiatric disturbances and contraindication in pregnancy
Solution Approach 1:
The patent applies the intermediary principle by introducing a new chemical structure (Formula I) that serves as an intermediate between existing antiprotozoal agents and the desired therapeutic outcome. This intermediary compound aims to achieve antiprotozoal activity comparable to quinacrine while eliminating its severe adverse effects including psychiatric disturbances and pregnancy contraindications.
Data Source
AI summary
The invention provides compounds of Formula (I), and their use in methods for treating or preventing a protozoan infection in a subject using a compound of Formula (I). The invention also provides the use of a compound of Formula (I) in the manufacture of a medicament for the treatment of a protozoan infection in a subject. The invention further provides a medical device when used in a method of treating or preventing a protozoan infection in a subject and to a medical device comprising the composition of the invention.